Danaher Corp
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher Devicor Medical / Mammotome by Year
Devicor Medical / Mammotome (Breast Biopsy & Cancer Diagnostics) — FDA 510(k) Clearances
Danaher Devicor Medical / Mammotome: 0 in FY2025, down 100.0% from a year earlier. That is the lowest of the 10 years on record here.
Where the FY2025 figure comes from
Source: U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Reported in U.S. FDA openFDA Device 510(k) Clearances API.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Danaher Devicor Medical / Mammotome, annual FY2016–FY2025 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/ext-fda-510k-mammotome-devicor
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.